Progress in, and future prospects for, the treatment of primary pulmonary hypertension

Heart

Volumn 86, Issue 6, 2001, Pages 603-604

  Wilkins, M R ^a   Wharton, J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE;

ANTIHYPERTENSIVE THERAPY; EDITORIAL; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT OUTCOME;

EID: 0035185914     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.86.6.603     Document Type: Editorial

References (18)

1. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
2. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial
3. Trials of inhaled lloprost and other new vasodilating prostaglandins
4. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
5. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells
6. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue
7. Efficacy and safety of chronic subcutaneous infusion UT-15 in pulmonary arterial hypertension (PAH)
8. Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension
9. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension
10. Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue
11. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension
12. Bosentan, a dual endothelin receptor antagonist, improves exercise capacity, and haemodynamics in patients with pulmonary arterial hypertension: Results of a double blind, randomized, placebo-controlled trial
13. Sildenafil inhibits hypoxia-induced pulmonary hypertension
14. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension
15. Sildenafil in primary pulmonary hypertension
16. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene
17. Heterozygous germline mutations in BMPR2, encoding a TGF-ß receptor, cause familial primary pulmonary hypertension
18. Controlling TGF-beta signaling